DGIdb - BIMATOPROST Drug Record

BIMATOPROST chembl:CHEMBL1200963 Approved

Alternate Names:

LATISSE
LUMIGAN
BIMATOPROST
AGN-192024
BIMATOPROSTUM
(Z)-7-((1R,2R,3R,5S)-3,5-DIHYDROXY-2-((1E,3S)-3-HYDROXY-5-PHENYL-1-PENTENYL)CYCLOPENTYL)-N-ETHYL-5-HEPTENAMIDE
LS-181817
LUMIGAN®
AGN 192024
chembl:CHEMBL1200963
rxcui:283810
chemidplus:155206-00-1
drugbank:00905
pubchem.compound:5311027

Drug Info:

FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antiglaucomic agent
Drug Class	antiglaucomic agents
Year of Approval	2001
Drug Categories	eicosanoids
Drug Categories	cytochrome p-450 cyp3a substrates
Drug Categories	cytochrome p-450 cyp3a4 substrates
Drug Categories	cytochrome p-450 cyp3a5 substrates
Drug Categories	cytochrome p-450 substrates
Drug Categories	drugs that are mainly renally excreted
Drug Categories	prostaglandin analogs reducing intraocular pressure (iop)

(3 More Sources)

Publications:

Sharif et al., 2003, Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells., J Ocul Pharmacol Ther
Wan et al., 2007, Bimatoprost, prostamide activity, and conventional drainage., Invest. Ophthalmol. Vis. Sci.
Sharif et al., 2002, Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor., J Ocul Pharmacol Ther
Sharif et al., 2001, Bimatoprost and its free acid are prostaglandin FP receptor agonists., Eur. J. Pharmacol.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Lim et al., 2008, Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study., Ophthalmology
Neacsu, 2009, [Receptors involved in the mechanism of action of topical prostaglandines]., Oftalmologia
Mintz, 1978, Group supervision: an experiential approach., Int J Group Psychother
Ota et al., 2006, The effects of prostaglandin analogues on prostanoid EP1, EP2, and EP3 receptor-deficient mice., Invest. Ophthalmol. Vis. Sci.
Gabelt et al., 2009, Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys., J Ocul Pharmacol Ther

BIMATOPROST PTGFR

Interaction Score: 14.48

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Full agonist

PMIDs:
14733708 17724194 12222762 11740958 11752352 18452763 19697832 689791

Sources:
TEND TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions
BIMATOPROST PTGER3

Interaction Score: 5.26

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name bimatoprost, AGN 192024,Lumigan

Novel drug target Established target

PMIDs:
14733708 16877408 19232013

Sources:
TdgClinicalTrial DrugBank
BIMATOPROST PTGER1

Interaction Score: 3.61

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name bimatoprost, AGN 192024,Lumigan

Novel drug target Established target

PMIDs:
14733708 16877408

Sources:
TdgClinicalTrial DrugBank

DrugBank: DB00905

Version: 5.1.7

Alternate Names:

BIMATOPROST DrugBank Drug Name

155206-00-1 CAS Number

Apo-bimatoprost Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Publications:

Sharif et al., 2003, Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells., J Ocul Pharmacol Ther

Ota et al., 2006, The effects of prostaglandin analogues on prostanoid EP1, EP2, and EP3 receptor-deficient mice., Invest. Ophthalmol. Vis. Sci.

Gabelt et al., 2009, Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys., J Ocul Pharmacol Ther

TEND: BIMATOPROST
- Version: 01-August-2011
Alternate Names:

BIMATOPROST Primary Drug Name

Drug Info:

Year of Approval 2001

Drug Class antiglaucomic agents

Publications:
TdgClinicalTrial: BIMATOPROST
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antiglaucomic agent

Drug Class Small Molecule

FDA Approval approved

Publications:
TTD: Bimatoprost
- Version: 2020.06.01
Alternate Names:

D0Q2XF TTD Drug ID

Drug Info:

Publications:
GuideToPharmacology: 135649995
- Version: 29-September-2020
Alternate Names:

BIMATOPROST GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1200963
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1200963
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Direct Interaction?	True
Endogenous Drug?	False
Specific Action of the Ligand	Full agonist

Trial Name	bimatoprost, AGN 192024,Lumigan
Novel drug target	Established target

BIMATOPROST	DrugBank Drug Name
155206-00-1	CAS Number
Apo-bimatoprost	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Groups	investigational

BIMATOPROST Drug Record

BIMATOPROST chembl:CHEMBL1200963 Approved

Alternate Names:

Drug Info:

Publications:

BIMATOPROST PTGFR

Interaction Types & Directionality: agonist (activating)

Interaction Info: Direct Interaction? True Endogenous Drug? False Specific Action of the Ligand Full agonist

PMIDs: 14733708 17724194 12222762 11740958 11752352 18452763 19697832 689791

Sources: TEND TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions

BIMATOPROST PTGER3

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name bimatoprost, AGN 192024,Lumigan Novel drug target Established target

PMIDs: 14733708 16877408 19232013

Sources: TdgClinicalTrial DrugBank

BIMATOPROST PTGER1

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name bimatoprost, AGN 192024,Lumigan Novel drug target Established target

PMIDs: 14733708 16877408

Sources: TdgClinicalTrial DrugBank

DrugBank: DB00905

Alternate Names: BIMATOPROST DrugBank Drug Name 155206-00-1 CAS Number Apo-bimatoprost Drug Brand

Drug Info: Drug Type small molecule Drug Groups approved Drug Groups investigational

TEND: BIMATOPROST

Alternate Names: BIMATOPROST Primary Drug Name

Drug Info: Year of Approval 2001 Drug Class antiglaucomic agents

Publications:

TdgClinicalTrial: BIMATOPROST

Alternate Names:

Drug Info: Drug Indications antiglaucomic agent Drug Class Small Molecule FDA Approval approved

Publications:

TTD: Bimatoprost

Alternate Names: D0Q2XF TTD Drug ID

Drug Info:

Publications:

GuideToPharmacology: 135649995

Alternate Names: BIMATOPROST GuideToPharmacology Ligand Name

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1200963

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL1200963

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Full agonist

PMIDs:
14733708 17724194 12222762 11740958 11752352 18452763 19697832 689791

Sources:
TEND TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name bimatoprost, AGN 192024,Lumigan

Novel drug target Established target

PMIDs:
14733708 16877408 19232013

Sources:
TdgClinicalTrial DrugBank

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name bimatoprost, AGN 192024,Lumigan

Novel drug target Established target

PMIDs:
14733708 16877408

Sources:
TdgClinicalTrial DrugBank

Alternate Names:

BIMATOPROST DrugBank Drug Name

155206-00-1 CAS Number

Apo-bimatoprost Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Alternate Names:

BIMATOPROST Primary Drug Name

Drug Info:

Year of Approval 2001

Drug Class antiglaucomic agents

Drug Info:

Drug Indications antiglaucomic agent

Drug Class Small Molecule

FDA Approval approved

Alternate Names:

D0Q2XF TTD Drug ID

Alternate Names:

BIMATOPROST GuideToPharmacology Ligand Name